Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Indole Tryptophan Metabolism and Cytokine S100B in Children with Attention-Deficit/Hyperactivity Disorder: Daily Fluctuations, Responses to Methylphenidate, and Interrelationship with Depressive Symptomatology.

Fernández-López L, Molina-Carballo A, Cubero-Millán I, Checa-Ros A, Machado-Casas I, Blanca-Jover E, Jerez-Calero A, Madrid-Fernández Y, Uberos J, Muñoz-Hoyos A.

J Child Adolesc Psychopharmacol. 2020 Feb 12. doi: 10.1089/cap.2019.0072. [Epub ahead of print]

PMID:
32048862
2.

BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology.

Cubero-Millán I, Ruiz-Ramos MJ, Molina-Carballo A, Martínez-Serrano S, Fernández-López L, Machado-Casas I, Tortosa-Pinto P, Ruiz-López A, Luna-Del-Castillo JD, Uberos J, Muñoz-Hoyos A.

Psychopharmacology (Berl). 2017 Jan;234(2):267-279. doi: 10.1007/s00213-016-4460-1. Epub 2016 Nov 3.

PMID:
27807606
3.

Differential responses of two related neurosteroids to methylphenidate based on ADHD subtype and the presence of depressive symptomatology.

Molina-Carballo A, Justicia-Martínez F, Moreno-Madrid F, Cubero-Millán I, Machado-Casas I, Moreno-García L, León J, Luna-Del-Castillo JD, Uberos J, Muñoz-Hoyos A.

Psychopharmacology (Berl). 2014 Sep;231(17):3635-45. doi: 10.1007/s00213-014-3514-5. Epub 2014 Mar 6.

PMID:
24599397
4.

Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes.

Cubero-Millán I, Molina-Carballo A, Machado-Casas I, Fernández-López L, Martínez-Serrano S, Tortosa-Pinto P, Ruiz-López A, Luna-del-Castillo JD, Uberos J, Muñoz-Hoyos A.

Int J Mol Sci. 2014 Sep 25;15(9):17115-29. doi: 10.3390/ijms150917115.

5.

Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD.

Molina-Carballo A, Naranjo-Gómez A, Uberos J, Justicia-Martínez F, Ruiz-Ramos MJ, Cubero-Millán I, Contreras-Chova F, Augustin-Morales MD, Khaldy-Belkadi H, Muñoz-Hoyos A.

J Psychiatr Res. 2013 Mar;47(3):377-83. doi: 10.1016/j.jpsychires.2012.09.020. Epub 2012 Oct 22.

PMID:
23088865
6.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
7.

Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.

Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.

J Child Adolesc Psychopharmacol. 2017 Aug;27(6):474-482. doi: 10.1089/cap.2017.0084. Epub 2017 Jul 21.

8.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
9.

Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.

Childress A, Mehrotra S, Gobburu J, McLean A, DeSousa NJ, Incledon B.

J Child Adolesc Psychopharmacol. 2018 Feb;28(1):10-18. doi: 10.1089/cap.2017.0044. Epub 2017 Oct 17.

10.

Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism--effects of medication.

Oades RD, Dauvermann MR, Schimmelmann BG, Schwarz MJ, Myint AM.

Behav Brain Funct. 2010 May 28;6:29. doi: 10.1186/1744-9081-6-29.

11.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

12.
13.

Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.

Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J.

J Am Acad Child Adolesc Psychiatry. 2013 Sep;52(9):921-30. doi: 10.1016/j.jaac.2013.06.006. Epub 2013 Aug 1.

PMID:
23972694
14.
15.

A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.

Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL.

Pediatrics. 1999 Dec;104(6):1300-11.

PMID:
10585981
16.

Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.

Kang KD, Yun SW, Chung U, Kim TH, Park JH, Park IH, Han DH.

Hum Psychopharmacol. 2016 Mar;31(2):76-82. doi: 10.1002/hup.2514. Epub 2016 Jan 12.

PMID:
26756111
17.

Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?

Golubchik P, Kodesh A, Weizman A.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):141-5. doi: 10.1097/WNF.0b013e31829eb204.

PMID:
24045603
18.

Effect of Ferritin on Short-Term Treatment Response in Attention Deficit Hyperactivity Disorder.

Oner P, Oner O, Cop E, Munir KM.

Klinik Psikofarmakol Bulteni. 2012;22(4):325-331. doi: 10.5455/bcp.20120403015900. Epub 2016 Nov 8.

19.

Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.

Coghill DR, Banaschewski T, Lecendreux M, Zuddas A, Dittmann RW, Otero IH, Civil R, Bloomfield R, Squires LA.

Eur Child Adolesc Psychiatry. 2014 Feb;23(2):61-8. doi: 10.1007/s00787-013-0421-y. Epub 2013 May 25.

20.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303

Supplemental Content

Support Center